跳至主要内容
临床试验/NCT03003156
NCT03003156已完成不适用

50 Hz vs. 25 Hz Magnetic Seizure Therapy for Schizophrenia

Shanghai Mental Health Center1 个研究点 分布在 1 个国家目标入组 18 人开始时间: 2016年2月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
18
试验地点
1
主要终点
changes of The Positive and Negative Syndrome Scale (PANSS)

研究概览

简要总结

This trial attempts to investigate whether the dosage (frequency) has an effect on the treatment efficacy and cognitive outcomes of magnetic seizure therapy (MST) among schizophrenia patients. Half of the participants will be recruited to receive 25 Hz MST, while the other half will be recruited to 50 Hz MST.

详细描述

Magnetic seizure therapy (MST) is likely to be an alternative options to electroconvulsive therapy (ECT).Widespread stimulation of cortical and subcortical regions is inevitable for ECT since the substantial impedance of the scalp and skull shuts most of the electrical stimulus away from the brain. Nevertheless, magnetic pulses are capable to focus the stimulus to a specific area of the brain because they can pass the scalp and skull without resistance. In Addition, electric current will penetrate into deeper structures, while magnetic stimulus are only capable to reach a depth of a few centimeters. As a consequence, MST are able to generate focus stimuli on superficial regions of the cortex while ECT can't, which may give MST the capability to produce comparable therapeutic benefits with the absence of apparent cognitive side effects. Though high dose (frequency) MST is gaining popularity, there is no evidences supporting its superiority over low dose (frequency) MST either on efficacy, safety, or seizure quality.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • DSM-5 diagnosis of schizophrenia;
  • convulsive therapy clinically indicated, such as severe psychomotor excitement or retardation, attempts of suicide, being highly aggressive, pharmacotherapy intolerance, and ineffectiveness of antipsychotics;
  • the positive and negative syndrome scale (PANSS)[20] score ≥ 60;
  • informed consent in written form.

排除标准

  • diagnosis of other mental disorders;
  • severe physical diseases, such as stroke, heart failure, liver failure, neoplasm, and immune deficiency;
  • present with a laboratory abnormality that could impact on efficacy of treatments or safety of participants;
  • failure to respond to an adequate trial of ECT lifetime;
  • are pregnant or intend to get pregnant during the study;
  • other conditions that investigators consider to be inappropriate to participate in this trial.

结局指标

主要结局

changes of The Positive and Negative Syndrome Scale (PANSS)

时间窗: At baseline, 4-week follow-up

次要结局

  • changes of The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)(At baseline and 4-week follow-up)
  • Adverse events(up to 4 weeks)
  • seizure duration(at each treatment session, up to 4 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验